Relypsa Presents New Data on the Importance of Renin-Angiotensin-Aldosterone-System Inhibitor (RAASi) Therapy in Patients With Cardio-Renal Comorbidities at the Academy of Managed Care Pharmacy's 27th Annual Meeting
08 avr. 2015 08h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that results from retrospective analyses of a large medical database...
Relypsa Announces New Employment Inducement Grants
06 avr. 2015 08h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 1, 2015, the compensation committee of the company's...
Relypsa Presents Sub-Group Analysis From Phase 3 Study of Patiromer FOS in Patients With Advanced Chronic Kidney Disease at 2015 National Kidney Foundation Spring Clinical Meeting
26 mars 2015 19h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from a Phase 3 clinical program showing that Patiromer for...
Relypsa Announces New Employment Inducement Grants
18 mars 2015 08h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on March 2, 2015, the compensation committee of the company's...
Relypsa Highlights Multiple Presentations of Patiromer for Oral Suspension at the 2015 World Congress of Nephrology
16 mars 2015 08h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today highlighted multiple data presentations of Patiromer for Oral Suspension (FOS)...
Relypsa Announces Phase 2 Data Showing Efficacy of Patiromer FOS in Heart Failure Patients With Chronic Kidney Disease at ACC Scientific Session
14 mars 2015 08h30 HE
|
Relypsa, Inc.
Sub-group Analysis of AMETHYST-DN Trial Results Led by Bertram Pitt, M.D.
Sponsored Panel at ACC Led by Prominent Thought Leader, Dr. Ileana L. Piña, will Review the Latest Data in Management...
Relypsa Announces Fourth Quarter and Full Year 2014 Financial Results
11 mars 2015 16h10 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31,...
Relypsa Announces New Employment Inducement Grants
04 mars 2015 16h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on March 2, 2015, the compensation committee of the company's...
Relypsa Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
03 mars 2015 16h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,485,000 shares of its common...
Relypsa to Present at 27th Annual ROTH Conference
02 mars 2015 08h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Kristine M. Ball, senior vice president and chief financial officer, will present at the 27th...